4 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 3 | Terminated 3 |
Follow Onureg: new trials by email Literature Review of Onureg trials Research Report on Onureg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies | Phase 2 | Terminated | Gilead Sciences | 54 | 2021-06-28 | 2025-03-20 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 110 | 2020-07-28 | 2026-04-23 |
| Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Azacitidine, Venetoclax - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 51 | 2019-10-01 | 2026-02-12 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Hematologic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
M.D. Anderson Cancer Center (3) · Gilead Sciences (1)
United States (4) · Australia (1) · United Kingdom (1)
Guillermo Garcia-Manero (1) · Naval G Daver (1) · Naval G Daver, MD (1)